GlassScriptPhysician profile
Michael D Cogburn
NPI 1912972811
$21,262.79
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,164 · 2021: $4,193 · 2022: $187 · 2023: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.29 |
| Education | $103.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $16,382.88 | 2019-2021 | |
| Merz North America, INC. | $1,463.93 | 2019 | |
| Janssen Biotech, INC. | $542.41 | 2019-2023 | Tremfya |
| Abbvie INC. | $442.84 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $398.40 | 2019-2023 | Ilumya, Odomzo, Blu-U |
| Genzyme Corporation | $289.35 | 2019-2023 | |
| Lilly USA, LLC | $229.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $168.09 | 2019-2022 | |
| Amgen INC. | $147.48 | 2020-2021 | |
| Genentech USA, INC. | $133.94 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $120.56 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $120.18 | 2019-2020 | |
| Pfizer INC. | $103.48 | 2019-2021 | |
| Leo Pharma INC. | $92.38 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $77.27 | 2019-2023 | Dupixent |
| Celgene Corporation | $74.93 | 2019 | |
| Almirall LLC | $51.53 | 2019-2020 | |
| Ucb, INC. | $45.85 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $39.66 | 2020 | |
| Biofrontera INC. | $37.67 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $35.26 | 2019 | |
| Journey Medical Corporation | $33.15 | 2019-2020 | |
| Allergan, INC. | $30.02 | 2019 | |
| Epi Health, LLC | $26.19 | 2020-2021 | |
| Dermavant Sciences, INC. | $20.43 | 2023 | Vtama |
| Dermira, INC. | $18.65 | 2020 | |
| Mission Pharmacal Company | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cogburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.